Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2022-12-19 14:32:49ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer
-
ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric CancerDaiichi Sankyo2022-12-19 14:33:43ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
-
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early TrialsDaiichi Sankyo2022-12-09 10:52:07Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in
-
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast CancerDaiichi Sankyo2022-12-09 10:53:06Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR
-
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03Daiichi Sankyo2022-12-08 13:03:04ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus
-
Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMODaiichi Sankyo2022-09-06 16:18:42Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
-
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2022-08-18 15:27:02ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice
-
ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based RegimensDaiichi Sankyo2022-08-18 15:16:38ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More
-
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenDaiichi Sankyo2022-08-18 15:09:25Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic
-
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative DiseaseDaiichi Sankyo2022-06-23 16:27:20Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic
